Here is the synopsis of our sample research paper on Why Pharmaceutical Companies Focus On A Disease. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
A 6 page paper. The paper begins with an explanation of the time and costs of developing a new drug. The writer shifts to the companies now focusing on developing new drugs to treat diabetes type 2 and why they are doing so. Some comments are made about organizational structure. Bibliography lists 5 sources.
Page Count:
6 pages (~225 words per page)
File: MM12_PGpdiab8.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
altruistic. Like any other industry, pharmaceutical companies exit to earn a profit. The average American understands this (the profit part) completely every time they have to fill a doctors prescription.
Admittedly, it costs hundreds of millions of dollars to develop a new drug and a company can spend those millions and not succeed. As Masia (2008) said: "Finding new
cures is an extremely expensive and risky proposition." The actual cost of developing varies from hundreds of millions to two or three billion dollars and those costs will continue
to rise (Masia, 2008). Very few new drugs are developed with a subsidy from the U.S. government, paying for it is left to the private sector although the incentive or
idea for a new drug may be spurred by government-funded research at university labs (Masia, 2008). Typically, scientist in the industry must review and study and sort through thousands of
new chemical inventions that may look promising for the cure or treatment of a disease or condition (Masia, 2008). Scientists whittle down the thousands of ideas to a
couple of hundred compounds that will be used in laboratory tests and then, in animals (Masia, 2008). Typically, the company finds fewer than 10 compounds that show enough promise and
potential to make it through to the next step, the Phase 1 human testing trials (Masia, 2008). This is a very healthy small group of people who take the
drug to discover if it is safe and effective for the disease (Masia, 2008). If the compound passes this step, the process moves to Phase 2 where the drug is
tested on a small group of people who actually have that disease (Masia, 2008). If successful, it moves to Phase 3, a controlled study, where the drug is used on
...